vancomycin cnp pharma 500 mg proszek do sporządzania roztworu do infuzji
cnp pharma gmbh - vancomycini hydrochloridum - proszek do sporządzania roztworu do infuzji - 500 mg
vancomycin cnp pharma 1000 mg proszek do sporządzania roztworu do infuzji
cnp pharma gmbh - vancomycini hydrochloridum - proszek do sporządzania roztworu do infuzji - 1000 mg
ezetymib aristo 10 mg tabletki
aristo pharma gmbh - ezetimibum - tabletki - 10 mg
voxzogo
biomarin international limited - vosoritide - achondroplasia - leki stosowane w leczeniu chorób kości - voxzogo is indicated for the treatment of achondroplasia in patients 4 months of age and older whose epiphyses are not closed. the diagnosis of achondroplasia should be confirmed by appropriate genetic testing.
dupixent
sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - Środki do zapalenia skóry, z wyłączeniem kortykosteroidy - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.
bosentan sandoz gmbh 125 mg tabletki powlekane
sandoz gmbh - bosentanum - tabletki powlekane - 125 mg
doppelsil max 50 mg tabletki do rozgryzania i żucia
doppelherz pharma gmbh - sildenafilum - tabletki do rozgryzania i żucia - 50 mg
doppelsil 25 mg tabletki do rozgryzania i żucia
doppelherz pharma gmbh - sildenafilum - tabletki do rozgryzania i żucia - 25 mg
bosentan sandoz gmbh 62,5 mg tabletki powlekane
sandoz gmbh - bosentanum - tabletki powlekane - 62,5 mg
tresuvi 1 mg/ml roztwór do infuzji
amomed pharma gmbh - treprostinilum - roztwór do infuzji - 1 mg/ml